Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 30:24:7750-7758.
doi: 10.12659/MSM.911585.

Expression of Micro-RNA-492 (MiR-492) in Human Cervical Cancer Cell Lines is Upregulated by Transfection with Wild-Type P53, Irradiation, and 5-Fluorouracil Treatment In Vitro

Affiliations

Expression of Micro-RNA-492 (MiR-492) in Human Cervical Cancer Cell Lines is Upregulated by Transfection with Wild-Type P53, Irradiation, and 5-Fluorouracil Treatment In Vitro

Mei Liu et al. Med Sci Monit. .

Abstract

BACKGROUND The status of p53 is critical to the chemoradiosensitivity of cervical cancer cells. Wild-type p53 is essential to orchestrate the cellular response to cytotoxic stimuli. Our previous data illustrated that cervical cancer patients whose specimens overexpressed microR-492 (miR-492) were highly sensitive to concurrent chemoradiation. Although p53 activation has been reported to upregulate miR-492 by a miRNA profiling assay in lung cancer cells, the transcriptional regulation of miR-492 in cervical cancer cells remains poorly understood. Therefore, we aimed to decipher the relationship between p53 and miR-492 in cervical cancer cells. MATERIAL AND METHODS The expression of p53 and miR-492 in cervical cancer cell lines was measured by western blot and real-time PCR. After cells were transfected with wild-type p53 plasmid or were treated by irradiation and 5-fluorouracil (5-FU), the expression changes of p53 as well as miR-492 were examined by western blot and real-time PCR. The putative p53 binding site of miR-492 was first analyzed by bioinformatics tools, then validated by chromatin immunoprecipitation and dual-luciferase reporter assays. RESULTS We found that miR-492 was upregulated in cells with wild-type p53 compared to cells with mutant p53. Transfection of wild-type p53 plasmid or treatments with cytotoxic reagents including irradiation and 5-FU all induced miR-492 overexpression. Bioinformatics analysis and experimental validations further proved p53 interacted with miR-492 promoter directly. CONCLUSIONS In cervical cancer cells, p53 activated miR-492 expression transcriptionally.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None.

Figures

Figure 1
Figure 1
Expression of p53 and miR-492 in cervical cancer cell lines. (A) The protein expression of p53 in C-33A, SiHa, and HeLa cells was detected by western blot; β-actin was used as an internal control. Quantification of p53 expression was performed by using Gel-Pro Analyzer 3.1 software. (B) miR-492 expression was examined by qRT-PCR with U6 as an internal control. All values were represented as means ±SD from at least 3 individual experiments.
Figure 2
Figure 2
MiR-492 expression was induced by p53. (A, B) HeLa and SiHa cells were transiently transfected with wild-type p53 expression plasmid pCMV-Neo-Bam p53 wt or its control vector, and the levels of p53 and miR-492 were examined by western blot and qRT-PCR. Expression changes of p53 and miR-492 were also detected when SiHa cells were treated with 8 Gy with 6 MV x-ray irradiation for 24, 48, or 72 hours (C, D), or exposed to different concentrations of 5-FU for 20 hours (E, F) by using western blot and qRT-PCR. The densitometric measurement was conducted with each western blot analysis. All data were shown as means ±SD from at least 3 individual experiments. * P<0.05.
Figure 3
Figure 3
Features of the miR-492 promoter region. (A) Schematic representation of p53 BS position in the miR-492 promoter region. The sequence of putative p53 response element of miR-492 was compared with the consensus p53 BS in detail. Besides, p53 BS of miR-492 was conserved among 7 primate species. The sequences were derived from the UCSC Genome Browser, and the tandem repeats of consensus p53 binding motifs in miR-492 promoter were highlighted with blue. (B) Promoter sequence 2 kb upstream and 1 kb downstream of the pre-miR-492 was visualized on the UCSC Genome Browser. Upper panel: The histone post-transcriptional modifications including H3K4me1, H3K4me3, and H3K27Ac of miR-492 promoter were presented from GM12878, H1-hESC, and HSMM cell lines, as determined by the ChIP-seq assays from ENCODE data. Lower panel: DNase cluster tracks showed DNase I hypersensitivity areas. The black or gray box indicated a higher degree of DNase I hypersensitivity. The number of cell lines hypersensitive to DNase I in the putative p53 BS was shown, as well. The locus of p53 BS was highlighted with purple. BS – binding site; ChIP – chromatin immunoprecipitation.
Figure 4
Figure 4
MiR-492 expression was directly regulated by p53. (A) ChIP analysis of p53 enrichment at the promoter region of miR-492 was performed with SiHa and HeLa cells. The chromatin segments bound to p53 or control IgG were purified and further analyzed by semi-quantitative PCR with primers surrounding the p53 BS. (B) p53 BS transcriptional activity with or without 5-FU induction was validated by dual-luciferase reporter assays. pGL3-basic construct harboring wild-type or mutant p53 BS or the control vector was transfected into SiHa cells together with pRL-SV40 as an internal control with or without 300 μM 5-FU for 20 hours. Data were represented as means ±SD from 3 independent experiments, * P<0.05. ChIP – chromatin immunoprecipitation; 5-FU – 5-fluorouracil.

Similar articles

Cited by

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. Cancer J Clin. 2015;65:87–108. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. - PubMed
    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–32. - PubMed
    1. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost. Int J Cancer. 2004;109:418–24. - PMC - PubMed
    1. Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015;13(4):395–404. quiz 404. - PubMed